Cognition Therapeutics President and CEO Lisa Ricciardi discusses the FDA considering the approval of a new Alzheimer's drug and the progress being made in the space to help combat the disease.
Quest Diagnostics on Monday released the first blood test for consumer purchase that can help assess the risk of developingThe AD-Detect Test for Alzheimer's Disease costs $399 and is available for purchase online and can assess a person's risk based on a brain protein that contributes to the condition, according to Quest.
Quest said its screening test uses plasma from a single blood draw to evaluate levels of amyloid beta proteins – which can form plaques in the brain and are linked to the progression of Alzheimer's disease – to help detect early signs associated with the risk of developing the disease.The innovation comes as the landscape for Alzheimer's disease care rapidly changes with new and emerging therapies.
"We are seeing much attention on emerging therapies for Alzheimer's disease, but with new treatment options will come the need to make screening and diagnosis more widely available," said Dr. Michael Racke, medical director of neurology for Quest Diagnostics. Dr. Seth Gale points out evidence of Alzheimer’s disease on an MRI at the Center for Alzheimer Research and Treatment at Brigham And Women’s Hospital in Boston, Massachusetts, on March 30, 2023.